+ Watch PPHM
on My Watchlist
A biopharmaceutical company with a portfolio of clinical stage and pre-clinical product candidates using monoclonal antibodies for the treatment of cancer and viral diseases.
Peregrine is advancing two novel cancer drug candidates that, combined with its hybrid business model, present attractive risk-reward opportunities in our view. Lead candidate bavituximab (bavi') has recently endured negative news flow, increasing skepticism from investors but creating a potential buying opportunity
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions